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The study of hematopoiesis has been a focus for
developmental biologists for over 100 years. What
started as a series of microscopic observations in
different animal model systems has since evolved into
studies of gene expression and regulation, and
subsequent protein–protein interactions, cell surface
protein expression profiling, and functional mapping
of cell fates. In this review, we will discuss the
milestone discoveries that have been achieved in the
field of hematopoietic development, as well as the
techniques that have been employed. Finally, we look
toward the future and consider unresolved questions.
We also reflect on one of the earliest realizations
made in this area of study: that hematopoiesis is
evolutionarily conserved, and as a consequence we
reflect on the impacts of early and current discoveries
and their clinical implications. The future direction of
the study of hematopoietic stem cells will probably
make use of pluripotent stem cells to yield specific
immune cell lineages and eventual clinical
applications.vanced hematopoietic progenitors isolated from theIntroduction
The hematopoietic developmental process has been stud-
ied in detail since the early 1900s. While ER Clark first
reported the observation of vascular generation in tad-
poles in 1909, and Stockard described blood-vessel devel-
opment and coined the term angioblast in fish embryos
in 1915, it was not until 1920 that F Sabin described the
formation of blood cells through the angioblast ‘liquefy-
ing’ within the aorta [1-3]. Since then several milestones
have been achieved in understanding this complex and
highly conserved developmental process.* Correspondence: jczp@sri.utoronto.ca
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article, unless otherwise stated.Basic hematopoietic development concepts
Mouse hematopoiesis was thought to develop initially in
the yolk sac, where primitive hematopoietic develop-
ment occurs [4]. This development is also often referred
to as fetal hematopoiesis, and was demonstrated by the
production of embryonic erythrocytes that still possess a
nucleus, express fetal hemoglobin, and lack any lymph-
oid potential [5]. This initial wave of fetal hematopoietic
development appears to have short-term reconstituting
function, as demonstrated by Dieterlen-Lievre using
chicken–quail chimeras [6]. The translatability of these
experiments across different biological systems such as
in Xenopus laevis and Danio rerio also demonstrates that
this process is conserved across several species [2,7-9].
Further studies in mice by Cumano and colleagues
sought to address the issue of an anatomical origin of
the long-term (LT) reconstituting hematopoietic stem
cell (HSC) found in adult animals [10]. Early in murine
embryonic development, hematopoietic progenitors can
be found in the para-aortic splanchnopleura region on
embryonic day 7 (as depicted in Figure 1A), but these
progenitors are not LT reconstituting although they do
possess lymphoid potential [11-13]. These more ad-
aorta–gonad–mesonephros (AGM) region at embryonic
day 9.5 to 10 can give rise to lymphoid lineages and are
LT reconstituting definitive HSCs, but since this time
point is after the establishment of the circulatory system
in the embryo their source was difficult to determine
[13]. Cumano and colleagues’ approach was to culture
explants containing hematopoietic progenitors isolated
from the yolk sac and the embryo proper before the on-
set of circulation, and to determine their LT reconstitu-
tion potential [10]. Their results indicated that yolk sac
progenitors before the onset of circulation did not have
LT reconstitution potential while progenitors isolated
from the AGM did, which indicates that primitive and
definitive hematopoiesis may occur at distinct anatomical
locations [10]. Overall, they demonstrated that the defini-
tive HSC differs from the primitive HSC by lymphoidoMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Primitive and definitive hematopoietic development. (A) Distinct anatomical regions of primitive and definitive hematopoietic
development in both the mouse and human. (B) Subset of cell surface markers used in the characterization of this developmental process.
CD309, vascular endothelial growth factor receptor 2; CD202b, Tie2 or angiopoietin receptor 2; CD41, integrin 2 alpha; CD45, leukocyte common
antigen.
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tution following transfer into adult recipients. More re-
cently, definitive hematopoietic development has also
been suggested to possibly occur during fetal ontogeny in
subsets of endothelial cells in the heart [14].
Human hematopoietic development in vivo
The study of in vivo hematopoietic development in
humans is less understood relative to the mouse model
due to limitations in experimental approaches. However,
evidence resulting from studies in the human embryo
has indicated that definitive HSCs emerge in the embryo
proper from aortic endothelium similar to observations
made in the mouse [15,16]. Morphological studies also
observed that HSC clusters can be found within the hu-
man aorta, and that these cells express CD34 (sialomucin,
a marker to enrich for early hematopoietic progenitors)
and CD45 (leukocyte common antigen), markers associ-
ated with the HSC fate [15]. Further similarities with the
mouse model include the site of initial HSC formation
within the aorta and subsequent hepatic colonization
[15,17,18], and that definitive hematopoietic cells are de-
rived from within the embryo and not the yolk sac [15,19].
In vitro hematopoietic development
Given the observations made in animal models, several
embryonic stem cell (ESC)-based in vitro developmental
models have been established in the last 20 years. The
two arguably most widely used models are the embryoid
body system developed by the Keller group [20] and theOP9 co-culture system developed by the Honjo and
Nakano groups [21,22].
Embryoid bodies are generated by aggregating ESCs,
and cells expressing vascular endothelial growth factor
receptor 2 (CD309) are thus induced to differentiate
[20]. By isolating CD309-expressing cells and forming an
aggregate, a hemangioblast is produced that can give rise
to multipotent hematopoietic cells, which can give rise
to erythroid, myeloid, and lymphoid lineages but are not
capable of LT reconstitution in vivo [20,23]. On the
other hand, by culturing ESCs with OP9 stromal cells,
derived from the op/op mice that lack the colony-
stimulating factor 1 gene, it is also possible to partially
recapitulate hematopoietic development [21]. The prod-
ucts of this developmental model are also multipotent
hematopoietic cells capable of erythroid, myeloid, and
lymphoid development but not capable of achieving LT
reconstitution [21,23]. In vitro ESC hematopoietic devel-
opmental models therefore clearly lacked fundamental
components that could support the development of de-
finitive HSCs in culture, which prompted further re-
search into the signaling pathways that form the basis of
this developmental program.
The concept of supporting bone-marrow hematopoietic
development with stromal cells is not a new one. Prior to
the OP9 stromal co-cultures becoming mainstream, earl-
ier predecessors such as the stromal cultures utilizing
mouse kidney cells and cells derived from whole embryo
tissue were also noted for their capacity to support myelo-
poiesis [24]. The importance of supporting stromal cells
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tion and isolation of several key cytokines involved in
hematopoiesis. Other stromal culturing methods using
primary mouse bone-marrow stromal cells coupled to
media containing bovine or horse serum, as well as ana-
lysis of the impact of steroids in culturing conditions, were
also instrumental in optimizing contemporary OP9 stro-
mal culturing conditions [25,26].
Assays used to study functional outcomes of
hematopoietic development
Many methods have been developed to assay the process
of hematopoietic development, both in vitro and in vivo.
While there are many protocols for assaying a myriad of
molecular and functional outcomes, all of these methods
can be categorized into two groups: functional assays
and phenotypic/morphological assays.
Phenotypic and morphological assays focus on the
characterization of this developmental process by meas-
uring distinct features that appear at specific time points.
The oldest technique within this category is microscopy.
Reported over 100 years ago and still relevant today,
hematopoietic cells are distinguished from the stromal en-
vironment by their nonadherent cell morphology [1,27].
Time-lapse microscopy in conjunction with advanced
techniques of fluorescent labels has repeatedly demon-
strated this process occurring with a marked shifting of
cell morphology, from adherent cell to nonadherent cell
[7-9]. However, morphological observations have their
limitations. The inability to efficiently isolate specific cells
from a complex mixture based on appearance poses chal-
lenges to define developmental intermediates undergoing
hematopoiesis. This shortcoming is addressed with the
use of fluorescence-activated cell sorting, which character-
izes and isolates cell populations based on their protein
expression. Applying this technique to ESC into HSC de-
velopment, several surrogate markers have been identified
to be strongly associated with primitive hematopoietic
progenitors and subsequent developmental intermediates.
The most well known of these markers is Flk1 (vascular
endothelial growth factor receptor 2), found on hemangio-
blasts that are multipotent progenitors of hematopoietic
and endothelial cell lineages [20]. Other cell surface pro-
teins used in the identification of HSCs include the
Lineage−Sca1+cKit+ definition (Sca1, lymphocyte antigen
6A/E; cKit, or CD117 stem cell factor receptor) [28]. Some
cell surface markers used in this characterization process
are outlined in Figure 1B. Finally, because the hema-
topoietic developmental process is highly regulated and
complex, the number of regulatory factors involved is also
vast. The challenge of mapping out the regulatory network
in an effort to characterize this process by means of dis-
tinct signal transduction and transcription regulation
pathways is met with experimental techniques commonlyfound in molecular biology. From the simple assays such
as polymerase chain reaction and western analysis to com-
plex and high-throughput gene arrays and chromatin im-
munoprecipitation sequencing experiments, transcription
factors such as runt related protein 1 (Runx1, or acute
myeloid leukemia 1) and lim domain binding 1 (Ldb1)
have been identified to play crucial roles [29-31].
However, characterization of distinct features that ap-
pear during this process – whether this is a protein or
gene being expressed or a cell shifting into a specific
shape – does not enable functional outcomes to be de-
termined. The definition of a hematopoietic progenitor
is one based on function and not on morphology or
phenotype. A host of functional assays have therefore
been developed and used in conjunction with the
methods mentioned above. The gold standard of all
functional assays is of course in vivo reconstitution. Suc-
cessful serial reconstitution of immune-deficient animals
is the hallmark of a definitive HSC [28]. Short of in vivo
models, in vitro assays such as methyl cellulose and
Matrigel have been used to demonstrate hematopoietic
and endothelial potential at a clonal level.
While there are many methods available for the func-
tional characterization of cells and populations, the diffi-
culty of determining the pluripotency of a single cell is
always present. This challenge can be met directly by
assessing the pluripotency and developmental potential
of single cells through the analysis of paired daughter
cells [32]. This method is perhaps the most direct to
functionally assess the developmental potential of pro-
genitors, at the single-cell level. While the method is
cumbersome and whether it presents a physiological en-
vironment for assessing developmental outcomes is de-
bated, this analysis nonetheless permitted the discovery
of key cytokines that can influence lineage fate choices
in hematopoietic progenitors.
Molecular mechanisms of hematopoietic
development
At the core of the molecular mechanisms of this highly
complex and regulated process is Runx1 (or acute mye-
loid leukemia 1 protein) [33]. Okuda and colleagues gen-
erated a Runx1 knockout mouse and discovered that
this genetic perturbation is embryonically lethal [33].
More interestingly, when the mouse was examined
closely there were signs of primitive hematopoiesis, but
not of definitive hematopoiesis [33]. Runx1 was thus
established as a key transcription factor in the definitive
hematopoietic development program.
Other transcriptional regulators that act upstream of
Runx1 include the Ldb1–Lim motif 2–stem cell leukemia
protein–GATA box binding protein 2 protein complex
that drives the expression of Runx1 [29,34] (Figure 2). De-
ficiency in Ldb1 abrogates the expression of Runx1 [29].
Figure 2 Transcriptional regulators in the definitive
hematopoietic development program. Lim-domain-binding 1
(Ldb1) stabilizes a complex of transcription factors involving Lim-motif
2 (Lmo2), stem cell leukemia (Scl), and GATA box binding protein 2
(GATA2) [29]. During hematopoietic differentiation, this complex
induces the expression of runt related protein 1 (Runx1), which is
required for definitive hematopoiesis, as reported previously [27].
Surface marker analysis revealed that generation of CD41+ cells is
impaired in the absence of Ldb1.
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hematopoietic developmental program towards the car-
diac smooth muscle lineage [30,31]. Finally, GATA box
binding protein 2 loss of function also results in embry-
onic lethality [35]. Downstream of Runx1 are transcription
factors that play distinct roles in erythroid, myeloid, and
lymphoid developmental programs such as GATA box
binding protein 1, PU box binding protein 1 (SPI1), and
Runx1 itself, respectively [36-38].
Given that the main components of hematopoietic
development depend heavily on multifactorial transcrip-
tional regulating protein complexes that can perform
multiple functions depending on the context of their
interactions, it is less likely that the hematopoietic
developmental program is governed in a linear network
connected by distinct signal transduction proteins or
protein complexes where defined outcomes arise from
a narrow set of inputs. Rather, this process is prob-
ably regulated in a probabilistic manner similar to a
quantum computer architecture, where a defined input
can lead to multiple outputs at varying probabilities
based on the context of those inputs. The inputs in this
case would be a combination of cell–cell interactions as
well as cytokine signals, and the output would be cell
fate choices and the associated functional properties.
Supporting this notion are studies of de-differentiation
and the findings that indicate multiple unstable, dynam-
ically regulated, intermediate states during somatic to
embryonic de-differentiation [39]. If there was such a
process where environmental cues are kept under full
control and development follows a linear path, there
would be no stochastic outcomes observed. However,
the observations of stochastic developmental results in-
dicate a much more elegant, probabilistic regulatory net-
work that requires far fewer nodes of control and
regulation.Signaling pathways involved in hematopoietic
development
As a complex and highly regulated process, there are
multiple signaling molecules – both intrinsic as well as
extrinsic – that contribute to the development of an
HSC. The best known of these signaling molecules is
Notch. Disruption of Notch signaling during embryonic
development leads to vascular and cardiac abnormalities,
as it is required for the endothelial to mesenchymal dif-
ferentiation that forms the stromal niche [40-42]. The
formation of this stromal niche via Notch1 signaling is
required for the embryonic development of HSCs, as
well as for HSC specification by inducing the expression
of Runx1 possibly through the Ldb1 complex [43,44].
Upstream of Notch1 is signaling via vascular endothelial
growth factor alpha by precursors of HSCs, and prior to
this are signaling events mediated by sonic hedgehog,
which are received by stromal cells and induce the pro-
duction of vascular endothelial growth factor alpha [44].
Other factors that contribute either to the development
or specification of the HSC lineage or to the develop-
ment of the stromal niche that supports this process in-
clude the Nodal/bone morphogenic protein 4/Wnt3a
pathways and signaling via fibroblast growth factor [44].
Figure 3 illustrates this process and the potential players
involved in early hematopoietic development.
Hematopoietic stem cell maintenance
As mentioned above, the in vitro hematopoietic develop-
mental models designed with ESCs can only achieve a par-
tial recapitulation of the hematopoietic process observed
in vivo. The key deficiency with in vitro models is the lack
of LT reconstitution potential in the multipotent hema-
topoietic cells that are produced [23]. This has been an
area of intense research, and the Daley group recently
showed that this is possible by activating signaling pro-
grams downstream of homeobox protein B4 (HoxB4) [45].
By ectopically expressing HoxB4 in ESCs via retroviral
vectors, the Daley group successfully demonstrated that
the resulting hematopoietic cells generated in vitro could
achieve LT reconstitution, as well as maintaining their
multipotent property [45] (shown in Figure 4). This obser-
vation has prompted research into the role of HoxB4 in
hematopoietic development and HSC self-renewal [46-49].
Given the clinical potential for HOXB4 in conditioning
HSCs ex vivo prior to transplantation, more attention
has also been given to the factors that can directly con-
trol the expression of HOXB4. One such recent report
has implicated GATA box binding protein 2 as a direct
upstream regulator of HOXB4 in CD34+ cells [50].
Current challenges and controversies
Despite the achievement of the above-mentioned mile-
stones, much still remains uncertain regarding the origin
Figure 3 Signaling factors involved in mammalian embryonic hematopoietic development. Initially, to form the stromal environment
supportive of hematopoietic development, Nodal/bone morphogenic protein 4 (bmp4)/Wnt3a is required for patterning of the primitive streak. Once
the stromal environment is established, sonic hedgehog (Shh) secreted by the notochord induces the production of vascular endothelial growth
factor alpha (VEGFa) by stromal cells, which signal to activate the transcription of Notch1 in hematopoietic precursors. Notch1 signaling then induces
the transcription of members of the Lim-domain-binding 1 (Ldb1) complex, which in turn induces the transcription of runt related protein 1 (Runx1).
GATA2, GATA box binding protein 2; Lmo2, Lim-motif 2; Scl, stem cell leukemia; Wnt3a, wingless-type MMTV integration site family, member 3A.
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subsequently fluorescence microscopy using tagged
proteins, such as CD309 and Runx1, indicated that
hematopoietic development occurs in close relationship
temporally and spatially with endothelial cell developmentFigure 4 Hematopoietic stem cell maintenance. Purified long-term
hematopoietic stem cells (HSCs) from adult animals can reconstitute
immune-deficient hosts in vivo. However, hematopoietic cells
generated in vitro cannot achieve the same functional outcome. The
self-renewal capacity can be induced with the expression of homeobox
B4 (HoxB4) ectopically in developing embryonic stem cells, indicating
that this potential is present although the trigger is unknown.[1,7-9]. A current issue of contention in this field of re-
search is in the connection between endothelial and
hematopoietic development. Hematopoietic cells have
been hypothesized to arise from a bipotent progenitor that
can give rise to endothelial cells as well as hematopoietic
cells, termed a hemangioblast [1,51]. However, there is
also a school of thought that hematopoietic cells arise
from a unique subset of endothelial cells, called the hemo-
genic endothelium [51-53]. Evidence from Huber and col-
leagues and Vogeli and colleagues indicated that a single
cell can give rise to endothelial and hematopoietic lineage
progeny, and these results served to support the heman-
gioblast hypothesis [27,54,55]. But there are caveats in
this approach, such as the misidentification of progeny
that express surface markers commonly associated with
mature endothelial cells, and the possibility that pre-
hematopoietic precursors may express the same surface
proteins cannot be ruled out. On the other hand, evi-
dence for the existence of a hemogenic endothelial cell
can be demonstrated by the in vivo developmental
morphology where a nonadherent hematopoietic cell can
be seen budding off from adherent cells in a possibly
unique type of cell division [7-9]. This approach also
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function and the definition of an endothelial cell is
mostly by its function as a structural component of the
vascular system [56].
In vitro studies utilizing genetic modifications that re-
sult in blocking hematopoietic development performed
by Okuda and colleagues, Chen and colleagues, and our
group have shown that it is possible to achieve endothe-
lial cell development in the absence of hematopoietic de-
velopment [33,57,58]. We also noted that the block in
hematopoietic development did not seem to allow a re-
direction towards the endothelial cell lineage even when
the genetic modification occurs upstream of Runx1 ex-
pression [58]. Therefore, it is more probable that endo-
thelial and hematopoietic cell development are regulated
under distinct but related programs, and may not occur
concurrently as the hemangioblast hypothesis would
predict.
Other areas of intense debate are found in ESC-
derived hematopoietic developmental models, and gen-
erally revolve around the common theme of the inability
of ESCs to give rise to in vivo reconstituting HSCs. The
first issue involves the characterization of this process
using cell surface markers. While it is well understood
that cell surface markers do not dictate the function of
the cell expressing them, although occasionally the func-
tion of those markers may allow us to infer function, it
is nonetheless very useful to identify distinct cell popula-
tions based on a defined set of cell surface markers that
are expressed or absent. Successful characterization
using this approach allows the process to be studied in
similar ways as other developmental pathways are stud-
ied, by taking full advantage of powerful techniques such
as fluorescence-activated cell sorting to isolate distinct
subsets of complex population mixtures to test for func-
tion both in vitro as well as in vivo. Over the last several
decades, this has not been achieved in a systematic and
thorough manner. Initially, CD309 was shown to be
expressed by endothelial cells at the site of hema-
topoietic differentiation in vivo [59]. Developing ESCs
were then characterized by CD105 (endoglin) expression
[60]. In mature HSCs, CD117 and Sca1 expression was
used for their identification as Lineage−Sca1+c-Kit+ cells
[28]. In all of the abovementioned reports, there may be
many markers characterized in total, but in each report
only a limited number of markers were analyzed in
sparse temporal windows of ESC hematopoietic develop-
ment. Characterizing the in vitro ESC hematopoietic de-
velopmental process using all of the abovementioned
markers and comparing the results with corresponding
in vivo subsets would be insightful.
When discussing controversies regarding in vitro ESC
hematopoietic development, we must also consider the
questions posed by the findings using ectopic expressionof HoxB4. While the functional outcome is clear, as
demonstrated by the Daley group, the mechanism is not
well understood [45]. Attempts at dissecting the tran-
scriptional regulatory programs involved following the
ectopic expression of HoxB4 in hematopoietic cells de-
rived from ESCs in vitro were performed by Oshima and
colleagues [49]. By studying the changes in gene expres-
sion in these cells, the authors found it possible to eluci-
date the activated pathways that are activated as a result;
however, since HoxB4 was ectopically expressed in ESCs
before the onset of differentiation, it is not clear whether
the changes in gene expression are the result of HoxB4
expression or a combination of cross-talk between
HoxB4-induced programs and feedbacks from the devel-
opmental environment. Furthermore, Lee and colleagues
also noted that ectopic expression of HOXB4 in human
ESCs did not yield the same effect as was observed in
murine ESCs [61]. Finding the gap between these two
systems will be critical in the translation of results from
studies in murine ESC hematopoietic development to-
ward the human system, eventually leading to clinical
applications.
Next steps
These abovementioned unanswered questions all have
the same aim, which is the successful generation of a LT
reconstituting HSC from an ESC in vitro. Although
there have been many significant discoveries made on
this topic, the next steps in answering these questions
will most probably take place in the field of high-
throughput genetic assays, followed by functional ana-
lysis. In the last decade, we have witnessed an explosion
in high-throughput technology that allows us to practic-
ally assay gene expression across genomes and test the
effects of cytokines, drugs, and chemicals across thou-
sands of biologically active samples. Using these tech-
niques it is possible to design experiments that generate
large amounts of data output, which could be analyzed
for patterns that may allow inference to function with ef-
fective analysis algorithms. High-throughput techniques
such as single-cell RNA expression analysis performed
by the Gottens group have successfully predicted novel
signaling cascades [62]. The number of publications that
contain chromatin-immunoprecipitation sequencing, an-
other high-throughput method of mapping the tran-
scriptome of specific populations of cells, as a keyword
in 2012 was 788, which is 21 times higher than those of
2008 [63].
Complementing the studies designed to elucidate the
transcriptional regulatory networks involved in embry-
onic hematopoietic development, there is also significant
interest in dissecting the epigenetic changes that occur
during this process, as well as the comparisons of epi-
genetic profiles between in vitro and in vivo derived
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differs between primitive and definitive hematopoiesis
in vivo [64]. This change is also accompanied by in-
creased demethylation at the distal promoter, which is
more prevalently utilized by definitive HSCs [64]. Find-
ings such as these prompt further investigation into the
role of methylation and other epigenetic events in rela-
tion to their functional impact upon hematopoiesis both
in vivo as well as in vitro.
Understanding of the cell intrinsic regulatory networks
and nodes of control cannot yield a complete picture
without consideration being given to cell extrinsic sig-
naling cues. Synchronized with the discoveries made for
cell intrinsic signaling pathways and epigenetic changes,
there has been considerable recent interest in showing
how cytokines can affect the lineage choice of progeni-
tors [65].
Conclusion
The study of this intricate developmental pathway over
the last century has been punctuated by several mile-
stone discoveries: the discovery that this is an evolution-
arily conserved process among many species, thus
yielding multiple experimental models to explore ques-
tions in hematopoiesis; the establishment and fine-tuning
of in vitro culture models that recapitulate virtually all
hematopoietic lineages, allowing questions of hema-
topoietic potential to be answered; and the advancements
in imaging as well as high-throughput methods such as
flow cytometry and gene arrays. By studying this system in
further detail – genetically, phenotypically, and function-
ally – its clinical applications are virtually as limitless as
the HSCs themselves.
With effective gene therapy, programming subsets of
cells such as T cells and B cells to target cancerous or in-
fectious cells and tissues can be applied to potential
treatments for congenital, oncological, and transmitted
hematological diseases. Translating the method for the
generation of HSCs from ESCs to induced pluripotent
stem cells would also make possible personalized med-
ical care, where donor matching would no longer be an
issue in bone marrow transplantation [66]. One study by
the Nakauchi group demonstrated that it is possible to
reprogram antigen-specific T cells and renew their func-
tional capacity through induced pluripotent stem cells
[67]. As another example that is closer to clinical appli-
cations, a biotech in the USA (Calimmune Inc., San
Diego, CA, USA) has recently started a clinical trial test-
ing Cal-1-modified hematopoietic stem/progenitor cells
for the treatment of HIV [68]. Finally, the characteriza-
tion of this developmental pathway opens the door to
disease modeling where pharmaceutical products can be
safely and effectively tested before proceeding with clin-
ical trials in human patients.Abbreviations
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